Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628997 | 1.00 | FAAH (0.38) | FAAHSLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL753367 | 0.83 | SLC1A2 (0.37) | FAAHSLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL28837332 | 0.83 | FAAH (0.38) | FAAHSLC1A1DPP4DPP9 | |
| SCHEMBL19486242 | 0.83 | FAAH (0.38) | FAAHSLC1A1DPP4DPP9 | |
| SCHEMBL25782046 | 0.81 | FAAH (0.37) | FAAH | |
| SCHEMBL9045357 | 0.80 | DPP7 (0.43) | SLC1A3SLC1A2SLC1A1DPP4DPP9 | |
| SCHEMBL6500352 | 0.80 | DPP7 (0.43) | SLC1A3SLC1A2SLC1A1DPP4DPP9 | |
| SCHEMBL5665430 | 0.79 | SLC7A5 (0.48) | FAAHSLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL6802258 | 0.79 | SLC7A5 (0.48) | FAAHSLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL24831969 | 0.78 | FAAH (0.35) | FAAHDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FAAH 602/4885SLC1A3 3605/4885SLC1A2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.